Pages that link to "Q36534026"
Jump to navigation
Jump to search
The following pages link to Chronic myeloid leukemia: diagnosis and treatment (Q36534026):
Displaying 50 items.
- Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia. (Q33756387) (← links)
- Substance use and survival after treatment for chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS). (Q33762874) (← links)
- Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor (Q33765281) (← links)
- A comprehensive analysis of breakpoint cluster region-abelson fusion oncogene splice variants in chronic myeloid leukemia and their correlation with disease biology (Q33785880) (← links)
- Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea (Q33828071) (← links)
- Methylation status of DDIT3 gene in chronic myeloid leukemia (Q33933648) (← links)
- Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia (Q34016866) (← links)
- Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia (Q34272962) (← links)
- Stem cells in clinical practice: applications and warnings (Q34552765) (← links)
- Development and targeted use of nilotinib in chronic myeloid leukemia. (Q34613968) (← links)
- Current and emerging treatment options in chronic myeloid leukemia (Q34618814) (← links)
- Monitoring response and resistance to treatment in chronic myeloid leukemia (Q34761663) (← links)
- MTHFR genetic polymorphisms may contribute to the risk of chronic myelogenous leukemia in adults: a meta-analysis of 12 genetic association studies (Q35079021) (← links)
- Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors (Q35595870) (← links)
- Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies (Q35794105) (← links)
- Three-way complex variant translocation involving short arm chromosome (1;9;22)(p36;q34;q11) in a chronic myeloid leukemia patient (Q35944604) (← links)
- Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy (Q36068354) (← links)
- Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing (Q36392598) (← links)
- Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia (Q36725262) (← links)
- Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias (Q36802620) (← links)
- A Novel Four-Way Complex Variant Translocation Involving Chromosome 46,XY,t(4;9;19;22)(q25:q34;p13.3;q11.2) in a Chronic Myeloid Leukemia Patient (Q36947496) (← links)
- Molecular oncology: current trends in diagnostics (Q37074135) (← links)
- Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years (Q37271941) (← links)
- Molecular biology of bcr-abl1-positive chronic myeloid leukemia (Q37283128) (← links)
- Treatment of myeloma: cure vs control (Q37284081) (← links)
- Programmed cell death 4 and BCR-ABL fusion gene expression are negatively correlated in chronic myeloid leukemia (Q37288747) (← links)
- Mental status changes after hematopoietic stem cell transplantation (Q37359876) (← links)
- Micro-osmotic pumps for continuous release of the tyrosine kinase inhibitor bosutinib in juvenile rats and its impact on bone growth (Q37366495) (← links)
- Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective (Q37580148) (← links)
- State-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment (Q37657478) (← links)
- Surrogate end points for long-term outcomes in chronic myeloid leukemia (Q38079249) (← links)
- A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase (Q38149613) (← links)
- Model-based cost-effectiveness analyses for the treatment of chronic myeloid leukaemia: a review and summary of challenges (Q38218300) (← links)
- Natural course and biology of CML. (Q38392667) (← links)
- Investigating critical genes and gene interaction networks that mediate cyclophosphamide sensitivity in chronic myelogenous leukemia (Q38432973) (← links)
- Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis (Q38452866) (← links)
- Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia. (Q38460343) (← links)
- What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid Leukemia: Two Case Reports and Review of the Literature (Q38708854) (← links)
- New Methodologies in the Molecular Monitoring of CML. (Q38762203) (← links)
- Monitoring disease burden in chronic myeloid leukemia: Past, present, and future (Q38802249) (← links)
- Molecular monitoring of chronic myeloid leukemia: present and future (Q38828713) (← links)
- Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy. (Q38843265) (← links)
- The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal (Q39125275) (← links)
- Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status (Q39319816) (← links)
- Down-regulation of hematopoiesis master regulator PU.1 via aberrant methylation in chronic myeloid leukemia (Q39335728) (← links)
- Association of Vascular Endothelial Growth Factor A (VEGFA) and its Receptor (VEGFR2) Gene Polymorphisms with Risk of Chronic Myeloid Leukemia and Influence on Clinical Outcome (Q40420700) (← links)
- A rare case of a three way complex variant positive Philadelphia translocation involving chromosome (9;11;22)(q34;p15;q11) in chronic myeloid leukemia: A case report (Q41153525) (← links)
- Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy (Q41948234) (← links)
- Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case (Q43117904) (← links)
- Utility values for specific chronic myeloid leukemia chronic phase health states from the general public in the United Kingdom (Q43519867) (← links)